2. Going Concern	3 Months Ended
Mar. 31, 2018
Notes
2. Going Concern:	2. Going Concern: At March 31, 2018 and December 31, 2017, the Company had cash of $57,989 and $20,191, respectively. It also had a working capital deficit of $387,194 and $292,377, respectively and an accumulated deficit of $1,960,173 and $1,403,928, respectively. This raises substantial doubt about the Company's ability to continue as a going concern. Management is taking action to ensure the Company will continue as a going concern for at least one year beyond the date of the issuance of the Company’s financial statements. From March 11, 2015 (Inception) through March 31, 2018, the Company has sold $664,342 in common stock. Common stock sales continue pursuant to the Company’s private placement offering. Additionally, the Company received approval for its Form S-1 Registration Statement with the Securities and Exchange Commission, through which it intends to offer for sale additional shares of its common stock. These fundraising efforts may not be successful. While there can be no assurances, management believes that these actions will enable the Company to continue as a going concern. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

2. Going Concern

3 Months Ended

Mar. 31, 2018

2. Going Concern:

At March 31, 2018 and December 31, 2017, the Company had cash of $57,989 and $20,191, respectively. It also had a working capital deficit of $387,194 and $292,377, respectively and an accumulated deficit of $1,960,173 and $1,403,928, respectively. This raises substantial doubt about the Company's ability to continue as a going concern. Management is taking action to ensure the Company will continue as a going concern for at least one year beyond the date of the issuance of the Company’s financial statements. From March 11, 2015 (Inception) through March 31, 2018, the Company has sold $664,342 in common stock. Common stock sales continue pursuant to the Company’s private placement offering. Additionally, the Company received approval for its Form S-1 Registration Statement with the Securities and Exchange Commission, through which it intends to offer for sale additional shares of its common stock. These fundraising efforts may not be successful. While there can be no assurances, management believes that these actions will enable the Company to continue as a going concern. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

IASO BioMed, Inc. 10-Q/A